UK markets closed
NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
78.85 +0.47 (+0.60%) GOLD FUTURES
2,324.30 +0.10 (+0.00%) DOW
38,957.62 +73.36 (+0.19%) Bitcoin GBP
49,870.88 -964.65 (-1.90%)
Agios Pharmaceuticals, Inc. (0HB0.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 05:17PM BST
| Previous close | 32.76 |
| Open | 32.42 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 31.92 - 32.42 |
| 52-week range | 20.13 - 35.35 |
| Volume | |
| Avg. volume | 522 |
| Market cap | 14.514M |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?
The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Simply Wall St.
Earnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Investors in Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) had a good week, as its shares rose 9.7% to close at US$34.54...
- Zacks
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
© 2024 Yahoo. All rights reserved.